Law360, New York (December 16, 2010, 4:58 PM ET) -- The Federal Trade Commission has launched the latest salvo in a battle with Watson Pharmaceuticals Inc. and others over settlements that blocked generic versions of testosterone replacement drug AngroGel, claiming that the drugmakers and a district court misinterpreted prior holdings from the appeals court overseeing the case.
Should the U.S. Court of Appeals for the Eleventh Circuit agree with the appellee companies' reading of its prior rulings, then it should reconsider those decisions en banc, the FTC told the appeals court in a reply brief filed...
FTC Urges 11th Circ. To Revive Pay-For-Delay Case
To view the full article, take a free trial now.
